Women with breast cancer will not benefit from a new drug that lasts eight months
Thousands of women with breast cancer cannot benefit from new drug lasting eight months after NHS approvalThe drug ribociclib, also known as Kisqali, can extend life by eight months Around 3,300 wo…
